Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy

IF 4.5 2区工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY

Cancer Nanotechnology Pub Date : 2023-03-28 DOI:10.1186/s12645-023-00177-8

J. Fu, F. Yao, Y. An, Xundou Li, Wenya Wang, Xian-da Yang

引用次数: 1

查看原文本刊更多论文

靶向PD-1和核仁素的新型双特异性适体用于癌症免疫治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

5.20

自引率

1.80%

发文量

审稿时长

15 weeks

期刊介绍： Aim: Recognizing cancer as a group of diseases caused by nanostructural problems (i.e. with DNA) and also that there are unique benefits to approaches inherently involving nanoscale structures and processes to treat the disease, the journal Cancer Nanotechnology aims to disseminate cutting edge research; to promote emerging trends in the use of nanostructures and the induction of nanoscale processes for the prevention, diagnosis, treatment of cancer; and to cover related ancillary areas. Scope: Articles describing original research in the use of nanostructures and the induction of nanoscale processes for the prevention, diagnosis and treatment of cancer (open submission process). Review, editorial and tutorial articles picking up on subthemes of emerging importance where nanostructures and the induction of nanoscale processes are used for the prevention, diagnosis and treatment of cancer.